What question did this study set out to answer?

To evaluate the effects of monoclonal antibodies against S100A8/9 on hematopoiesis and immune modulation in myeloid malignancies.

December 8, 2025BloodOpen Access

Monoclonal antibodies against pathogenic S100A8/9 alarmins can restore hematopoiesis and result in immunomodulation in myelodysplasia and leukemia models

View Full Paper

Ask AI

Bookmark

Authors

SASrinivas AluriAlbert Einstein College of Medicine SASarah AminovAlbert Einstein College of Medicine LKLeah KravetsAlbert Einstein College of Medicine

Discussion

Member takes

Implication

Neutralizing monoclonal antibodies improved hematopoiesis and reduced T-regulatory cell formation in myelodysplastic and leukemic conditions, suggesting therapeutic potential.

Key Points

To evaluate the effects of monoclonal antibodies against S100A8/9 on hematopoiesis and immune modulation in myeloid malignancies.
Analyzed bone marrow CD34+ cells from MDS patients and compared S100A8/9 receptor expression to healthy controls.
Generated neutralizing monoclonal antibodies targeting S100A8/9 via B-cell cloning from immunized rabbits.
Conducted functional assays using PBMC cultures to assess MDSC and T-reg formation suppression.
Assessed erythroid differentiation in primary MDS and AML cells grown ex vivo with monoclonal antibodies.
Higher S100A8/9 expression in MDS patients correlated with increased RBC transfusion dependency and lower hemoglobin levels.
Monoclonal antibodies inhibited the interaction of S100A8/9 with receptors, reducing MDSC and T-reg formation.
Treatment with neutralizing antibodies increased erythroid colony formation and differentiation, indicating restored hematopoiesis.

Cite This Study

Aluri et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d377 https://doi.org/10.1182/blood-2025-4959

View Full Paper

Ask AI

Bookmark

Implication

Neutralizing monoclonal antibodies improved hematopoiesis and reduced T-regulatory cell formation in myelodysplastic and leukemic conditions, suggesting therapeutic potential.

Monoclonal antibodies against pathogenic S100A8/9 alarmins can restore hematopoiesis and result in immunomodulation in myelodysplasia and leukemia models

Discussion

Member takes

Implication

Key Points

Cite This Study

Monoclonal antibodies against pathogenic S100A8/9 alarmins can restore hematopoiesis and result in immunomodulation in myelodysplasia and leukemia models

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider